81 related articles for article (PubMed ID: 26213291)
21. Anticancer evidence for zoledronic acid across the cancer continuum.
Costa L; Harper P; Coleman RE; Lipton A
Crit Rev Oncol Hematol; 2011 Feb; 77 Suppl 1():S31-7. PubMed ID: 21353179
[TBL] [Abstract][Full Text] [Related]
22. Zoledronic acid-induced cytotoxicity through endoplasmic reticulum stress triggered REDD1-mTOR pathway in breast cancer cells.
Lan YC; Chang CL; Sung MT; Yin PH; Hsu CC; Wang KC; Lee HC; Tseng LM; Chi CW
Anticancer Res; 2013 Sep; 33(9):3807-14. PubMed ID: 24023313
[TBL] [Abstract][Full Text] [Related]
23. Biodistribution and plasma protein binding of zoledronic acid.
Weiss HM; Pfaar U; Schweitzer A; Wiegand H; Skerjanec A; Schran H
Drug Metab Dispos; 2008 Oct; 36(10):2043-9. PubMed ID: 18625688
[TBL] [Abstract][Full Text] [Related]
24. Immediate Administration of Zoledronic Acid Reduces Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women With Early Breast Cancer: 12-month analysis of the E-ZO-FAST trial.
Llombart A; Frassoldati A; Paija O; Sleeboom HP; Jerusalem G; Mebis J; Deleu I; Miller J; Schenk N; Neven P
Clin Breast Cancer; 2012 Feb; 12(1):40-8. PubMed ID: 22014381
[TBL] [Abstract][Full Text] [Related]
25. Apoptosis Induced by Microbubble-Assisted Acoustic Cavitation in K562 Cells: The Predominant Role of the Cyclosporin A-Dependent Mitochondrial Permeability Transition Pore.
Zhao L; Feng Y; Shi A; Zong Y; Wan M
Ultrasound Med Biol; 2015 Oct; 41(10):2755-64. PubMed ID: 26164288
[TBL] [Abstract][Full Text] [Related]
26. Annual zoledronic acid for osteoporosis.
BMJ Group
Drug Ther Bull; 2008 Dec; 46(12):93-6. PubMed ID: 19056701
[TBL] [Abstract][Full Text] [Related]
27. In vitro and in vivo effects of photodynamic therapy on metastatic breast cancer cells pre-treated with zoledronic acid.
Akens MK; Wise-Milestone L; Won E; Schwock J; Yee AJ; Wilson BC; Whyne CM
Photodiagnosis Photodyn Ther; 2014 Sep; 11(3):426-33. PubMed ID: 25176573
[TBL] [Abstract][Full Text] [Related]
28. Anabolic and antiresorptive drugs improve trabecular microarchitecture and reduce fracture risk following radiation therapy.
Arrington SA; Fisher ER; Willick GE; Mann KA; Allen MJ
Calcif Tissue Int; 2010 Sep; 87(3):263-72. PubMed ID: 20563797
[TBL] [Abstract][Full Text] [Related]
29. Endocytotic uptake of zoledronic acid by tubular cells may explain its renal effects in cancer patients receiving high doses of the compound.
Verhulst A; Sun S; McKenna CE; D'Haese PC
PLoS One; 2015; 10(3):e0121861. PubMed ID: 25756736
[TBL] [Abstract][Full Text] [Related]
30. The role of zoledronic acid in the adjuvant treatment of breast cancer: current perspectives.
Tonyali O; Arslan C; Altundag K
Expert Opin Pharmacother; 2010 Nov; 11(16):2715-25. PubMed ID: 20977404
[TBL] [Abstract][Full Text] [Related]
31. Zoledronic acid for adjuvant use in patients with breast cancer.
Ressler S; Mlineritsch B; Greil R
Expert Rev Anticancer Ther; 2011 Mar; 11(3):333-49. PubMed ID: 21417849
[TBL] [Abstract][Full Text] [Related]
32. Zoledronic acid infusion for lumbar interbody fusion in osteoporosis.
Tu CW; Huang KF; Hsu HT; Li HY; Yang SS; Chen YC
J Surg Res; 2014 Nov; 192(1):112-6. PubMed ID: 24948545
[TBL] [Abstract][Full Text] [Related]
33. Zoledronic acid in the treatment of metastatic breast cancer.
Lluch A; Cueva J; Ruiz-Borrego M; Ponce J; Pérez-Fidalgo JA
Anticancer Drugs; 2014 Jan; 25(1):1-7. PubMed ID: 24100278
[TBL] [Abstract][Full Text] [Related]
34. Osteoclasts but not osteoblasts are affected by a calcified surface treated with zoledronic acid in vitro.
Schindeler A; Little DG
Biochem Biophys Res Commun; 2005 Dec; 338(2):710-6. PubMed ID: 16243296
[TBL] [Abstract][Full Text] [Related]
35. Once-yearly zoledronic acid in older men compared with women with recent hip fracture.
Boonen S; Orwoll E; Magaziner J; Colón-Emeric CS; Adachi JD; Bucci-Rechtweg C; Haentjens P; Kaufman JM; Rizzoli R; Vanderschueren D; Claessens F; Sermon A; Witvrouw R; Milisen K; Su G; Lyles KW;
J Am Geriatr Soc; 2011 Nov; 59(11):2084-90. PubMed ID: 22091563
[TBL] [Abstract][Full Text] [Related]
36. Effect of zoledronic acid on the doxycycline-induced decrease in tumour burden in a bone metastasis model of human breast cancer.
Duivenvoorden WC; Vukmirović-Popović S; Kalina M; Seidlitz E; Singh G
Br J Cancer; 2007 May; 96(10):1526-31. PubMed ID: 17437017
[TBL] [Abstract][Full Text] [Related]
37. The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis.
Zarogoulidis K; Boutsikou E; Zarogoulidis P; Eleftheriadou E; Kontakiotis T; Lithoxopoulou H; Tzanakakis G; Kanakis I; Karamanos NK
Int J Cancer; 2009 Oct; 125(7):1705-9. PubMed ID: 19521984
[TBL] [Abstract][Full Text] [Related]
38. Biomarker alterations with metronomic use of low-dose zoledronic acid for breast cancer patients with bone metastases and potential clinical significance.
Zhao X; Xu X; Guo L; Ragaz J; Guo H; Wu J; Shao Z; Zhu J; Guo X; Chen J; Zhu B; Wang Z; Hu X
Breast Cancer Res Treat; 2010 Dec; 124(3):733-43. PubMed ID: 20882405
[TBL] [Abstract][Full Text] [Related]
39. Zoledronic acid: a framework of emerging anticancer evidence throughout the cancer continuum.
Terpos E
Crit Rev Oncol Hematol; 2011 Feb; 77 Suppl 1():S1-2. PubMed ID: 21353175
[No Abstract] [Full Text] [Related]
40. Pharmacokinetics, pharmacodynamics, and safety of zoledronic acid in horses.
Nieto JE; Maher O; Stanley SD; Knych HK; Snyder JR
Am J Vet Res; 2013 Apr; 74(4):550-6. PubMed ID: 23531062
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
